Digital Annealer speeds up Polarisqb’s drug discovery platform 10,000 times faster than traditional molecular analysis
"Our expertise in chemistry and machine-learning, combined with Fujitsu’s technology and experience, means we can identify viable molecules quickly."
Accelerating drug discovery through collaboration
Polarisqb is a Research Triangle Park-based start-up which aims to transform global health through the rapid creation of drug blueprints for all human proteins, disease pathways, genetic mutations, and pathogens. The company combines the powers of quantum computing, AI, and precision medicine to research chemical space in order to create novel molecular drugs for specific proteins and diseases.
To accelerate the drug discovery process to fight diseases using quantum-inspired computing, machine-learning and QM/MM.
A platform combining Fujitsu’s Digital Annealer with Polarisqb’s chemistry and machine-learning algorithms to speed up drug discovery